Dean Fennell, FRCP, PHD, University Hospitals of Leicester NHS Trust, Leicester, UK, provides an overview of the role of immunotherapy in mesothelioma, highlighting the results from CheckMate 743 (NCT02899299) which are now the basis of standard of care in this patient population. The next stages include investigating the potential benefit of chemotherapy and immunotherapy combination approaches as well as implementing precision medicine. This interview took place at the European Lung Cancer Congress 2023 in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть